For the last 2 decades, the conservative treatment of CKD was mainly based on the pharmacological suppression of RAAS, with both AII-converting enzyme (ACE) inhibitors (ACEIs) and AII receptor blockers (ARBs), such as Losartan, associated to the control of CKD-predisposing factors (hypertension, hyperglycemia, hypercholesterolemia) and to the establishment of a healthy life style, with physical activity and a healthy diet. The gene discussed is ACE; the disease is chronic kidney disease.